COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY
Objective: To study the manifestations of anemia syndrome in patients with chronic myeloid leukemia (CML) depending on the stage of the disease and on the background of Gleevec, Hydrea and anti-anemic drugs. Methods: 117 patients with CML aged 16 to 85 years were examined. All patients were divid...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Avicenna Tajik State Medical University
2019-09-01
|
| Series: | Паёми Сино |
| Subjects: | |
| Online Access: | https://doi.org/10.25005/2074-0581-2019-21-3-380-386 |
| _version_ | 1797797492882931712 |
|---|---|
| author | K.Z. URAKOV V.YU. MELNIKOVA G.B. KHODZHIEVA |
| author_facet | K.Z. URAKOV V.YU. MELNIKOVA G.B. KHODZHIEVA |
| author_sort | K.Z. URAKOV |
| collection | DOAJ |
| description | Objective: To study the manifestations of anemia syndrome in patients with chronic myeloid leukemia (CML) depending on the stage of the disease and on the background of Gleevec, Hydrea and anti-anemic drugs.
Methods: 117 patients with CML aged 16 to 85 years were examined. All patients were divided into two groups: the first group consisted of 99 patients who received hydroxyurea (Hydrea), the second group – 18 patients who received imatinib (Gleevec). As a baseline therapy, patients in the first group took Hydrea at a dose of 500 mg per day, depending on the number of white blood cells; the dose of the Hydrea was adjusted from 1 to 3 capsules 3 times a day. Patients of the II group in the chronic phase were assigned Gleevec at a dose of 400 mg/day, and in the phase of accelerated and blast crisis – 600-800 mg/day for 5-32 months. At the level of hemoglobin (Hb) ≤ 100g/l patients of both groups were prescribed the drug recombinant erythropoietin – Epoetin alpha (EPO, repretin). The drug was administered subcutaneously 200 IU 2-3 times a week. The duration of EPO therapy was, on average, 10.1±4.6 days.
Results: The effectiveness of treatment was assessed by increasing the level of Hb to 120 g/l or increasing its level by 20 g/l or more. In the chronic phase of CML, anemia was detected in a small number of patients, Hb averaged 101.4± 8.9 g/l, while in the accelerating phase Hb was reduced to 92.1± 3.1 g/l. This was especially evident during the blast crisis when the HB level reached 70.6±2.6 g/l. The characteristic was the reduction of reticulocytes in parallel with the progression of the disease (1,0±0,5-0,6±0,1). Leukocytosis is the chronic stage was 98.2±25.2×109 /l, and with the transition to the stage of accelerating there was its increase to 115.7±12.5×109 /l. In the case of the development of the blast crisis in the terminal stage, leukocytosis reached 121.3 to 17.5×109 /l.
Conclusion: The severity of the manifestations of the anemic syndrome in patients with CML depends both on the stage of the disease and on the quality of the therapy. In a comparative aspect, slightly more favorable results were obtained in the group of patients receiving a combination of Gleevec and EPO. |
| first_indexed | 2024-03-13T03:49:11Z |
| format | Article |
| id | doaj.art-c373b2bb863e47e6b1dc9cba51327634 |
| institution | Directory Open Access Journal |
| issn | 2074-0581 2959-6327 |
| language | English |
| last_indexed | 2024-03-13T03:49:11Z |
| publishDate | 2019-09-01 |
| publisher | Avicenna Tajik State Medical University |
| record_format | Article |
| series | Паёми Сино |
| spelling | doaj.art-c373b2bb863e47e6b1dc9cba513276342023-06-22T19:23:36ZengAvicenna Tajik State Medical UniversityПаёми Сино2074-05812959-63272019-09-0121338038610.25005/2074-0581-2019-21-3-380-386COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPYK.Z. URAKOV0V.YU. MELNIKOVA1G.B. KHODZHIEVA2Department of Internal Diseases № 3, Avicenna Tajik State Medical University, Dushanbe, Republic of TajikistanDepartment of Internal Diseases № 3, Avicenna Tajik State Medical University, Dushanbe, Republic of TajikistanDepartment of Internal Diseases № 3, Avicenna Tajik State Medical University, Dushanbe, Republic of TajikistanObjective: To study the manifestations of anemia syndrome in patients with chronic myeloid leukemia (CML) depending on the stage of the disease and on the background of Gleevec, Hydrea and anti-anemic drugs. Methods: 117 patients with CML aged 16 to 85 years were examined. All patients were divided into two groups: the first group consisted of 99 patients who received hydroxyurea (Hydrea), the second group – 18 patients who received imatinib (Gleevec). As a baseline therapy, patients in the first group took Hydrea at a dose of 500 mg per day, depending on the number of white blood cells; the dose of the Hydrea was adjusted from 1 to 3 capsules 3 times a day. Patients of the II group in the chronic phase were assigned Gleevec at a dose of 400 mg/day, and in the phase of accelerated and blast crisis – 600-800 mg/day for 5-32 months. At the level of hemoglobin (Hb) ≤ 100g/l patients of both groups were prescribed the drug recombinant erythropoietin – Epoetin alpha (EPO, repretin). The drug was administered subcutaneously 200 IU 2-3 times a week. The duration of EPO therapy was, on average, 10.1±4.6 days. Results: The effectiveness of treatment was assessed by increasing the level of Hb to 120 g/l or increasing its level by 20 g/l or more. In the chronic phase of CML, anemia was detected in a small number of patients, Hb averaged 101.4± 8.9 g/l, while in the accelerating phase Hb was reduced to 92.1± 3.1 g/l. This was especially evident during the blast crisis when the HB level reached 70.6±2.6 g/l. The characteristic was the reduction of reticulocytes in parallel with the progression of the disease (1,0±0,5-0,6±0,1). Leukocytosis is the chronic stage was 98.2±25.2×109 /l, and with the transition to the stage of accelerating there was its increase to 115.7±12.5×109 /l. In the case of the development of the blast crisis in the terminal stage, leukocytosis reached 121.3 to 17.5×109 /l. Conclusion: The severity of the manifestations of the anemic syndrome in patients with CML depends both on the stage of the disease and on the quality of the therapy. In a comparative aspect, slightly more favorable results were obtained in the group of patients receiving a combination of Gleevec and EPO.https://doi.org/10.25005/2074-0581-2019-21-3-380-386chronic myeloid leukemiachronic stagestage of acceleratingrecombinant erythropoietingleevechydreaanemic syndrome. |
| spellingShingle | K.Z. URAKOV V.YU. MELNIKOVA G.B. KHODZHIEVA COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY Паёми Сино chronic myeloid leukemia chronic stage stage of accelerating recombinant erythropoietin gleevec hydrea anemic syndrome. |
| title | COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY |
| title_full | COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY |
| title_fullStr | COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY |
| title_full_unstemmed | COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY |
| title_short | COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY |
| title_sort | comparative assessment of anemic syndrome in patients with chronic myeloid leukemia on the background to the gleevec and hydrea therapy |
| topic | chronic myeloid leukemia chronic stage stage of accelerating recombinant erythropoietin gleevec hydrea anemic syndrome. |
| url | https://doi.org/10.25005/2074-0581-2019-21-3-380-386 |
| work_keys_str_mv | AT kzurakov comparativeassessmentofanemicsyndromeinpatientswithchronicmyeloidleukemiaonthebackgroundtothegleevecandhydreatherapy AT vyumelnikova comparativeassessmentofanemicsyndromeinpatientswithchronicmyeloidleukemiaonthebackgroundtothegleevecandhydreatherapy AT gbkhodzhieva comparativeassessmentofanemicsyndromeinpatientswithchronicmyeloidleukemiaonthebackgroundtothegleevecandhydreatherapy |